Clinical trial
Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients…
NCT00332163 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00332163 |
|---|---|
| Title | Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy |
| Official title | A Phase 2, Open-label, Randomized Clinical Trial of Skin Toxicity Treatment in Subjects Receiving Second-line FOLFIRI or Irinotecan Only Chemotherapy Concomitantly With Panitumumab |
| Acronym | STEPP |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Colorectal Cancer, Skin Rash, Skin Toxicities, Colon Cancer, Colorectal Cancer |
| Intervention type | Biological, Drug |
| Interventions | Panitumumab, Irinotecan, FOLFIRI, Pre-emptive Skin Treatment, Reactive Skin Treatment |
| Enrollment | 95 |
| Start date | Apr 1, 2006 |
| Primary completion | Jan 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Jun 1, 2006 |
| Last update posted | Feb 23, 2016 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: